StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Rubicon Research Limited (RUBICON)

Pharma · NSE · end-of-day 2026-10-19

₹1,486.70

Day change

-1.45%

1-year

+136.7%

From 52-week high

-20.1%

Weinstein stage

Stage 2

Minervini template

—

Rubicon Research Limited closed at ₹1,486.70 on 2026-10-19, up 137% over the past year, 20% below its 52-week high. Weinstein's stage analysis reads stage 2 - advancing. Over the year its annualised volatility was about 45%, with a largest fall of 21% from a peak.

About Rubicon Research Limited

Rubicon Research Limited develops and manufactures pharmaceutical products, including complex formulations and drug-delivery products for domestic and international markets. Its business benefits from demand for specialized and generic medicines. Product approvals, new launches and international expansion provide opportunities. Regulatory compliance, product approvals, R&D costs, raw-material prices, pricing pressure and competition remain important factors.

Price, RSI and MACD

6M1Y

Price · +60.3% over the period

RSI (14) · 32.0

MACD (12, 26, 9) · histogram -10.33

Price · +136.7% over the period

RSI (14) · 32.0

MACD (12, 26, 9) · histogram -10.33

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Debt / equity	Free cash flow	EV / EBITDA	Beta
₹24,587 cr	₹1,936 cr	₹288 cr	83.8	17.74	19.08	22.4%	0.20	₹-24 cr	61.3	0.34

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	534	85	5.13	—	—	15.9%
Mar 2026	514	77	4.66	—	—	14.9%
Dec 2025	476	73	4.46	—	—	15.3%
Sep 2025	412	54	3.49	—	—	13.1%

Consolidated · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 0 of 0 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	— Not assessable
EPS growth accelerating over 3 quarters	— Not assessable
Sales up 25%+, or sales growth accelerating	— Not assessable
Annual EPS up 25%+ in each of the last 2 years	— Not assessable
Net margin above the same quarter last year	— Not assessable

Investor methods

Method	Checks	Score	Verdict
Turtle	✗ Close above the prior 55-session high · 1,899.00 ✗ Close above the prior 20-session high · 1,827.50 ✗ Close below the prior 20-session low · 1,450.50 Donchian channel breakout - the Turtle traders' entry.		No signal
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 2 - advancing
Graham	✗ Price at or below the Graham number · Graham number 176.36 ✗ P/E 15 or less · P/E 83.8 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 19.08 ✓ Current ratio 2 or more · 2.01 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	12/100	Expensive

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
RUBICON this stock	-15.1	-1.7	+60.3	+140.3	—	—	83.8	19.08	22.4	—	—	0.20	61.3	24,587	1,936	288	17.7	0.34
BLISSGVS	-8.0	+29.9	+147.2	+312.3	+606.5	+476.9	48.7	5.57	11.5	16.8	—	0.00	29.3	6,650	1,005	142	12.9	1.10
VENUSREM	+0.7	-5.9	+55.8	+252.6	+518.8	+242.4	18.3	3.21	16.8	21.9	—	0.00	13.7	2,130	811	116	86.9	0.88
INDSWFTLAB	-5.7	+50.4	+153.3	+247.2	+287.1	+472.2	51.6	2.21	3.2	3.9	—	0.01	33.4	3,056	665	57	6.8	0.78
MOREPENLAB	+0.5	+108.6	+194.2	+152.6	+242.7	+132.7	47.5	5.34	7.9	10.1	—	0.16	40.2	6,657	1,951	140	2.6	1.46
SHILPAMED	-14.2	+40.1	+113.1	+146.1	+421.3	+189.7	57.3	6.61	9.8	11.4	—	0.25	—	17,130	1,682	297	15.3	0.87
LAURUSLABS	+5.9	+32.7	+83.2	+129.9	+421.9	+235.3	88.9	21.09	18.2	17.9	—	0.45	62.0	1.12L	8,839	1,252	23.3	0.74
ZIMLAB	+2.0	+14.2	+73.3	+101.9	+17.5	—	168.5	2.50	2.1	5.5	—	0.42	21.1	740	397	4	0.8	0.75
ACUTAAS	-5.4	-11.0	+35.0	+97.5	—	—	69.0	16.11	24.0	31.7	—	0.02	49.9	26,636	1,462	387	47.2	0.77
IOLCP	-9.8	+17.8	+108.9	+87.8	+99.0	+56.2	32.0	2.99	7.9	10.7	—	0.07	20.7	5,376	2,524	168	5.7	1.13
SENORES	-10.6	-9.5	+37.4	+75.3	—	—	44.1	6.18	14.1	15.3	—	0.35	29.5	5,773	692	131	28.4	0.95

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Neuland Laboratories Pplpharma Acutaas Sailife Granules India Wockpharma Pine Labs Limited Emcure Pharmaceuticals Limited

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact